Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Spores of Bacillus Clausii Probiotic Strain · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Spores of Bacillus Clausii Probiotic Strain | DRUG | - |
Inclusion criteria: Infants or Children * Non hospitalized infants or children * With acute diarrhea evident for less than 48 hours * Having had three or more watery stools during the preceding 24 hours Exclusion criteria: Infants or Children * With blood stools * Having been treated with antib...
Spores of Bacillus Clausii Probiotic Strain is an investigational probiotic being studied for the treatment of diarrhea. It is currently in Phase 3 clinical development and has been evaluated in a completed trial involving children with acute diarrhea.
Spores of Bacillus Clausii Probiotic Strain is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY.
Spores of Bacillus Clausii Probiotic Strain is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. A Phase 3 trial has been completed, but the product remains under investigation.
Spores of Bacillus Clausii Probiotic Strain has one completed Phase 3 trial, NCT00265369, titled 'TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children'. This randomized, double-blind study enrolled 420 participants in Belgium and France.
Spores of Bacillus Clausii Probiotic Strain refers to the probiotic formulation containing spores of the bacterium Bacillus clausii. The trial NCT00265369 specifically studied this strain in the context of acute diarrhea in children.